Treatment Outcome According to Presenting Features in Infants With ALL (n = 106)
| Feature . | n (%) . | pEFS ± SE (%) . | P Value . |
|---|---|---|---|
| Sex | |||
| Female | 55 (52) | 46 ± 7 | .35 |
| Male | 51 (48) | 39 ± 7 | |
| Age (mo) | |||
| <6 | 50 (47) | 32 ± 6 | .009 |
| ≥6 ≤ 12 | 56 (53) | 56 ± 7 | |
| WBC (×103/μL) | |||
| <100 | 46 (43) | 52 ± 8 | .04 |
| ≥100 | 60 (57) | 37 ± 6 | |
| BFM RF | |||
| <1.7 | 87 (82) | 47 ± 6 | .06 |
| ≥1.7 | 19 (18) | 26 ± 10 | |
| CNS disease | |||
| Present | 25 (24) | 19 ± 8 | .0008 |
| Absent | 81 (76) | 51 ± 6 | |
| Cytogenetics* | |||
| Evaluable | 59 | 38 ± 7 | |
| Normal | 18 (31) | 56 ± 12 | |
| 11q23 rearranged | 29 (49) | 28 ± 8 | .03 |
| t(4;11)† | 17 | 18 ± 9 | .004 |
| Other abnormalities | 12 (20) | 42 ± 14 | |
| Not evaluable | 47 | 50 ± 7 | |
| Immunophenotype* | |||
| Evaluable | 104 | ||
| B-lineage | |||
| Pro-B-ALL | 52 (50) | 30 ± 7 | .005 |
| c-/pre-B ALL | 47 (45) | 56 ± 7 | |
| pro-T | 3 (3) | ||
| AUL | 2 (2) | ||
| CD 10 | |||
| CD10− | 62 (59) | 35 ± 6 | .02 |
| CD10+ | 42 (41) | 55 ± 8 | |
| Myeloid marker (≥1) | |||
| Present | 29 (28) | 45 ± 6 | .7 |
| Absent | 75 (72) | 40 ± 9 | |
| Prednisone response*,‡ | |||
| Evaluable | 105 | ||
| Good (<1,000/μL) | 78 (74) | 53 ± 6 | .0001 |
| Poor (≥1,000/μL) | 27 (26) | 15 ± 7 |
| Feature . | n (%) . | pEFS ± SE (%) . | P Value . |
|---|---|---|---|
| Sex | |||
| Female | 55 (52) | 46 ± 7 | .35 |
| Male | 51 (48) | 39 ± 7 | |
| Age (mo) | |||
| <6 | 50 (47) | 32 ± 6 | .009 |
| ≥6 ≤ 12 | 56 (53) | 56 ± 7 | |
| WBC (×103/μL) | |||
| <100 | 46 (43) | 52 ± 8 | .04 |
| ≥100 | 60 (57) | 37 ± 6 | |
| BFM RF | |||
| <1.7 | 87 (82) | 47 ± 6 | .06 |
| ≥1.7 | 19 (18) | 26 ± 10 | |
| CNS disease | |||
| Present | 25 (24) | 19 ± 8 | .0008 |
| Absent | 81 (76) | 51 ± 6 | |
| Cytogenetics* | |||
| Evaluable | 59 | 38 ± 7 | |
| Normal | 18 (31) | 56 ± 12 | |
| 11q23 rearranged | 29 (49) | 28 ± 8 | .03 |
| t(4;11)† | 17 | 18 ± 9 | .004 |
| Other abnormalities | 12 (20) | 42 ± 14 | |
| Not evaluable | 47 | 50 ± 7 | |
| Immunophenotype* | |||
| Evaluable | 104 | ||
| B-lineage | |||
| Pro-B-ALL | 52 (50) | 30 ± 7 | .005 |
| c-/pre-B ALL | 47 (45) | 56 ± 7 | |
| pro-T | 3 (3) | ||
| AUL | 2 (2) | ||
| CD 10 | |||
| CD10− | 62 (59) | 35 ± 6 | .02 |
| CD10+ | 42 (41) | 55 ± 8 | |
| Myeloid marker (≥1) | |||
| Present | 29 (28) | 45 ± 6 | .7 |
| Absent | 75 (72) | 40 ± 9 | |
| Prednisone response*,‡ | |||
| Evaluable | 105 | ||
| Good (<1,000/μL) | 78 (74) | 53 ± 6 | .0001 |
| Poor (≥1,000/μL) | 27 (26) | 15 ± 7 |